Resources from the same session
129O - Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study
Presenter: Do-Youn Oh
Session: Proffered Paper session: Gastrointestinal tumours
Resources:
Abstract
Slides
Webcast
130O - The phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
Presenter: Sun Young Rha
Session: Proffered Paper session: Gastrointestinal tumours
Resources:
Abstract
Slides
Webcast
Invited Discussant - surgical perspective of 129O and 130O
Presenter: Jimmy So
Session: Proffered Paper session: Gastrointestinal tumours
Resources:
Slides
Webcast
Invited Discussant 129O and 130O
Presenter: Elizabeth Smyth
Session: Proffered Paper session: Gastrointestinal tumours
Resources:
Slides
Webcast
89O - Long-term outcomes of intraoperative chemotherapy with 5-FU for colorectal cancer patients receiving curative resection (IOCCRC): A randomized, multicenter, prospective, phase III trial
Presenter: Rongxin Zhang
Session: Proffered Paper session: Gastrointestinal tumours
Resources:
Abstract
Slides
Webcast
Q&A and discussion
Presenter: All Speakers
Session: Proffered Paper session: Gastrointestinal tumours
Resources:
Webcast
Q&A and discussion
Presenter: All Speakers
Session: Proffered Paper session: Gastrointestinal tumours
Resources:
Webcast